XTSX
VXL
Market cap961kUSD
May 22, Last price
0.01CAD
Name
Vaxil Bio Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.98%
Rev. gr., 5y
%
Revenues
0k
Net income
0k
L-99.96%
CFO
-561k
L-23.57%
Profile
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2015‑05 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 254 | 584 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (254) | (584) | ||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | (254) | (584) | ||||||||
Net income | (254) -99.96% | (584) -40.77% | ||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | (938) | (1,510) | ||||||||
| Cash flow | ||||||||||
Cash from operating activities | (561) | (734) | ||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | (254) | (582) | ||||||||
| Balance | ||||||||||
Cash | 938 | 1,510 | ||||||||
Long term investments | ||||||||||
Excess cash | 938 | 1,510 | ||||||||
Stockholders' equity | 891 | 812 | ||||||||
Invested Capital | 324 | |||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 136,978 | 136,979 | ||||||||
Price | 0.03 25.00% | 0.02 -73.33% | ||||||||
Market cap | 3,424 25.00% | 2,740 -73.16% | ||||||||
EV | 2,486 | 1,230 | ||||||||
EBITDA | (254) | (582) | ||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||